HRP20090594T1 - Upotreba aktiviranih polimera za odvajanje proteina i polipeptidnih multimera - Google Patents
Upotreba aktiviranih polimera za odvajanje proteina i polipeptidnih multimera Download PDFInfo
- Publication number
- HRP20090594T1 HRP20090594T1 HR20090594T HRP20090594T HRP20090594T1 HR P20090594 T1 HRP20090594 T1 HR P20090594T1 HR 20090594 T HR20090594 T HR 20090594T HR P20090594 T HRP20090594 T HR P20090594T HR P20090594 T1 HRP20090594 T1 HR P20090594T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- mpeg
- polypeptide
- use according
- activated polymer
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract 24
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 24
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 24
- 229920000642 polymer Polymers 0.000 title claims abstract 18
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 238000000926 separation method Methods 0.000 title 1
- 125000003172 aldehyde group Chemical group 0.000 claims 5
- 125000003277 amino group Chemical group 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- ASUGWWOMVNVWAW-UHFFFAOYSA-N 1-(2-methoxyethyl)pyrrole-2,5-dione Chemical compound COCCN1C(=O)C=CC1=O ASUGWWOMVNVWAW-UHFFFAOYSA-N 0.000 claims 3
- 150000001720 carbohydrates Chemical class 0.000 claims 3
- 235000014633 carbohydrates Nutrition 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000000468 ketone group Chemical group 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 claims 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Natural products CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 claims 1
- 125000003636 chemical group Chemical group 0.000 claims 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical group C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims 1
- 125000003700 epoxy group Chemical group 0.000 claims 1
- -1 hydroxysuccinimidyl group Chemical group 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 229920001427 mPEG Polymers 0.000 claims 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Abstract
Primjena aktiviranog polimera za odvajanje ne-kovalentno povezanih polipeptidnih multimera koji sadrže višestruke polipeptidne podjedinice u višestruke polipeptidne podjedinice, naznačena time da- se aktivirani polimer sastoji od kemijske skupine kojom se polimer može kovalentno vezati za polipeptidnu podjedinicu u ne-kovalentno povezani polipeptidni multimer- aktivirani polimer je aktivirani polietilen glikol, aktivirani polidekstran, ili aktivirani poli-L-lizin, te - svaka od polipeptidnih podjedinica sadrži jedan polipeptidni lanac; i /ili skupinu sa najmanje dva jednostruka polipeptidna lanca, gdje su najmanje dva jednostruka polipeptidna lanca kovalentno vezani jedan sa drugim i gdje barem jedna polipeptidna podjedinica sadrži jednostruki lanac antitijela koji se sastoji od najmanje jednog područja varijabilnih antitijela. Patent sadrži još 13 patentnih zahtjeva.
Claims (14)
1. Primjena aktiviranog polimera za odvajanje ne-kovalentno povezanih polipeptidnih multimera koji sadrže višestruke polipeptidne podjedinice u višestruke polipeptidne podjedinice, naznačena time da
- se aktivirani polimer sastoji od kemijske skupine kojom se polimer može kovalentno vezati za polipeptidnu podjedinicu u ne-kovalentno povezani polipeptidni multimer
- aktivirani polimer je aktivirani polietilen glikol, aktivirani polidekstran, ili aktivirani poli-L-lizin, te
- svaka od polipeptidnih podjedinica sadrži jedan polipeptidni lanac; i /ili skupinu sa najmanje dva jednostruka polipeptidna lanca, gdje su najmanje dva jednostruka polipeptidna lanca kovalentno vezani jedan sa drugim i gdje barem jedna polipeptidna podjedinica sadrži jednostruki lanac antitijela koji se sastoji od najmanje jednog područja varijabilnih antitijela.
2. Upotreba prema zahtjevu 1, naznačena time da aktivirani polimer ima molekularnu masu od najmanje 3.000 g / mol i sadrži 25 do 70 tež.% polarnih atoma, gdje su polarni atomi, atomi koji ulaze u interakcije s vodikovim vezama s molekulama vode u vodenoj otopini.
3. Upotreba prema zahtjevima 1 ili 2, naznačena time da je svaka od višestrukih polipeptidnih podjedinica u odvojenom obliku vezana za aktivirani polimer.
4. Upotreba prema zahtjevu 3, naznačena time da je svaka od višestrukih polipeptidnih podjedinica u odvojenom obliku kovalentno vezana za aktivirani polimer.
5. Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time da se jednostruki lanac antitijela sastoji od jednog ili dva područja varijabilnih antitijela.
6. Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time da se svaka polipeptidna podjedinica kovalentno veže na aktivirani polimer preko amino skupine, sulfhidril skupine, karboksilne skupine, hidroksilne skupine ili aldehidne skupine sadržane u/na polipeptidnoj podjedinici.
7. Upotreba prema zahtjevu 6, naznačena time da
• aktivirani polimer koji je u sposoban tvoriti kovalentnu kemijsku vezu s amino skupinom sadržanom unutar polipeptidne podjedinice sadrži hidroksisukcinimidilnu skupinu, karboksilnu skupinu, epoksidnu skupinu, keto skupinu ili aldehidnu skupinu;
• aktivirani polimer koji je u sposoban tvoriti kovalentnu kemijsku vezu sa sulfhidrilnom skupinom sadržanom unutar polipeptidne podjedinice sadrži maleimidnu skupinu, vinil sulfonsku skupinu ili sulfhidrilnu skupinu;
• aktivirani polimer koji je u sposoban tvoriti kovalentnu kemijsku vezu sa karboksilnom skupinom sadržanom unutar polipeptidne podjedinice sadrži amino skupinu ili hidroksilnu skupinu; i/ili
• aktivirani polimer koji je u sposoban tvoriti kovalentnu kemijsku vezu sa hidroksilnom skupinom sadržanom unutar polipeptidne podjedinice sadrži karboksilnu skupinu, aldehidnu skupinu ili keto skupinu.
8. Upotreba prema bilo kojem od zahtjeva od 3-7, naznačena time da je svaka polipeptidna podjedinica kovalentno vezana za aktivirani polimer putem ugljikohidrata sadržanog unutar polipeptidne podjedinice, gdje je ugljikohidrat kemijski modificiran kako bi sadržavao barem jednu aldehidnu skupinu.
9. Upotreba prema zahtjevu 8, naznačena time da aktivirani polimer koji je u stanju tvoriti kovalentnu kemijsku vezu s aldehidom skupinom koja sadrži ugljikohidrate sadrži amino skupinu ili hidrazidnu skupinu.
10. Upotreba prema zahtjevu 9, naznačena time da je kovalentna veza između aldehidne i amino skupine ili hidrazidne skupine stabilizirana reduktivnom animacijom.
11. Upotreba prema zahtjevu 1, naznačena time da je aktivirani polietilen elikol odabran iz skupine koja se sastoji od mPEG-SPA (mPEG-Sukcinimidil Propionata), mPEG-SBA (mPEG-Sukcinimidil Butanoata), mPEG-SMB (mPEG-Sukcinimidil alfa-metilbutanoata), mPEG2-NHS(mPEG2-N-hidroksisukcinimida), mPEG-OPTE (mPEG-tioestera), mPEG-CM-HBA-NHS (mPEG-karboksimetil-3-hidroksibutanojeva kiselina-N-hidroksisukcinata), mPEG-ACET (mPEG-Acetaldehid dietil acetala), mPEG2- Acetaldehida (ekvivalent za mPEG2-dietil acetal), mPEG-Propionaldehida, mPEG2-Propionaldehida, mPEG-Butiraldehida, mPEG2-Butiraldehida, mPEG-Ketona, mPEG-MAL (mPEG-Maleimida), mPEG2-MAL (mPEG2-Maleimida) i mPEG-Tiola.
12. Upotreba prema bilo kojem od prethodnih zahtjeva naznačena time da aktivirani polimer ima molekularnu težinu od 3,500 g/mol, 5,000 g/mol, 20,000 g/mol ili 40,000 g/mol.
13. Upotreba prema zahtjevu 11 ili zahtjevu 12 naznačena time da mPEG-MAL je mPEG-MAL ili mPEG2-MAL koji ima molekularnu težinu od 40,000 g/mol.
14. Upotreba prema bilo kojem od prethodnih zahtjeva naznačena time da aktivirani polimer sadrži:
• 27 do 60 % tež. polarnih atoma, posebice 32 do 45 % tež. polarnih atoma, od 35 do 38 % tež. polarnih atoma, ili
• od 36 do 37 % tež. polarnih atoma
• od 27 do 28 % tež. polarnih atoma
• od 48 do 50 % tež. polarnih atoma, ili
• od 54 do 56 % tež. polarnih atoma,
gdje su polarni atomi, atomi koji ulaze u interakcije s vodikovim vezama s molekulama vode u vodenoj otopini.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05003332 | 2005-02-16 | ||
| PCT/EP2006/001359 WO2006087178A1 (en) | 2005-02-16 | 2006-02-15 | Use of activated polymers for separation of protein and polypeptide multimers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090594T1 true HRP20090594T1 (hr) | 2009-12-31 |
Family
ID=36168573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090594T HRP20090594T1 (hr) | 2005-02-16 | 2009-11-04 | Upotreba aktiviranih polimera za odvajanje proteina i polipeptidnih multimera |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080312411A1 (hr) |
| EP (1) | EP1848458B1 (hr) |
| JP (1) | JP2008530163A (hr) |
| AT (1) | ATE447414T1 (hr) |
| AU (2) | AU2006215823A1 (hr) |
| CA (1) | CA2594666A1 (hr) |
| DE (1) | DE602006010176D1 (hr) |
| DK (1) | DK1848458T3 (hr) |
| ES (1) | ES2335304T3 (hr) |
| HR (1) | HRP20090594T1 (hr) |
| SI (1) | SI1848458T1 (hr) |
| WO (1) | WO2006087178A1 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5766118B2 (ja) * | 2008-09-11 | 2015-08-19 | ウェルズ ファーゴ バンク ナショナル アソシエイション | ポリマー性アルファ−ヒドロキシアルデヒドおよびケトン反応剤ならびに抱合方法 |
| US9315514B2 (en) | 2012-08-27 | 2016-04-19 | Rhodes Technologies | 1,3-dioxanomorphides and 1,3-dioxanocodides |
| US8937084B2 (en) | 2012-12-14 | 2015-01-20 | Purdue Pharma L.P. | Nitrogen containing morphinan derivatives and the use thereof |
| CA2894963A1 (en) | 2012-12-14 | 2014-06-19 | Purdue Pharma L.P. | Pyridonemorphinan analogs and biological activity on opioid receptors |
| ES2621305T3 (es) | 2012-12-14 | 2017-07-03 | Purdue Pharma Lp | Morfinanos espirocíclicos y su uso |
| TW201441199A (zh) | 2012-12-28 | 2014-11-01 | Purdue Pharma Lp | 經取代之嗎啡喃類及其用途 |
| WO2014102587A1 (en) | 2012-12-28 | 2014-07-03 | Purdue Pharma L.P. | 7,8-cyclicmorphinan analogs |
| US9834562B2 (en) | 2012-12-31 | 2017-12-05 | Rhodes Technologies | 7 beta-substituted 6a, 14a-ethenomorphinans and 7beta-substituted 6a, 14a-ethanomorphinans |
| WO2015097547A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | 10-substituted morphinan hydantoins |
| WO2015097548A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | 7-beta-alkyl analogs of orvinols |
| EP3087079B1 (en) | 2013-12-26 | 2019-04-03 | Purdue Pharma LP | Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans |
| US9340542B2 (en) | 2013-12-26 | 2016-05-17 | Purdue Pharma L.P. | Propellane-based compounds and the use thereof |
| WO2015102682A1 (en) | 2013-12-30 | 2015-07-09 | Purdue Pharma L.P. | Pyridone-sulfone morphinan analogs as opioid receptor ligands |
| MX2019007327A (es) | 2016-12-23 | 2019-09-02 | Minoryx Therapeutics S L | Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales. |
| AU2019224127B2 (en) | 2018-02-23 | 2021-12-09 | Rhodes Technologies | Novel opioid compounds and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5312808A (en) * | 1989-11-22 | 1994-05-17 | Enzon, Inc. | Fractionation of polyalkylene oxide-conjugated hemoglobin solutions |
| EP2295450B1 (en) * | 2000-09-29 | 2015-01-28 | Merck Sharp & Dohme Corp. | Pegylated interleukin-10 |
| WO2003000179A2 (en) * | 2001-06-22 | 2003-01-03 | Pharmacia Corporation | Chemically-modified progenipoietin conjugates |
-
2006
- 2006-02-15 WO PCT/EP2006/001359 patent/WO2006087178A1/en active Application Filing
- 2006-02-15 DE DE602006010176T patent/DE602006010176D1/de active Active
- 2006-02-15 AT AT06706962T patent/ATE447414T1/de active
- 2006-02-15 DK DK06706962.5T patent/DK1848458T3/da active
- 2006-02-15 EP EP06706962A patent/EP1848458B1/en active Active
- 2006-02-15 AU AU2006215823A patent/AU2006215823A1/en not_active Abandoned
- 2006-02-15 JP JP2007555522A patent/JP2008530163A/ja not_active Withdrawn
- 2006-02-15 ES ES06706962T patent/ES2335304T3/es active Active
- 2006-02-15 SI SI200630466T patent/SI1848458T1/sl unknown
- 2006-02-15 US US11/884,300 patent/US20080312411A1/en not_active Abandoned
- 2006-02-15 CA CA002594666A patent/CA2594666A1/en not_active Abandoned
-
2007
- 2007-11-27 AU AU2007237199A patent/AU2007237199A1/en not_active Withdrawn
-
2009
- 2009-11-04 HR HR20090594T patent/HRP20090594T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK1848458T3 (da) | 2010-02-01 |
| EP1848458A1 (en) | 2007-10-31 |
| DE602006010176D1 (de) | 2009-12-17 |
| US20080312411A1 (en) | 2008-12-18 |
| SI1848458T1 (sl) | 2010-01-29 |
| AU2006215823A1 (en) | 2006-08-24 |
| ATE447414T1 (de) | 2009-11-15 |
| AU2007237199A1 (en) | 2008-01-17 |
| JP2008530163A (ja) | 2008-08-07 |
| ES2335304T3 (es) | 2010-03-24 |
| EP1848458B1 (en) | 2009-11-04 |
| WO2006087178A1 (en) | 2006-08-24 |
| CA2594666A1 (en) | 2006-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090594T1 (hr) | Upotreba aktiviranih polimera za odvajanje proteina i polipeptidnih multimera | |
| Ahmadabadi et al. | Surface modification approaches for prevention of implant associated infections | |
| Kumar et al. | Antimicrobial peptide–polymer conjugates with high activity: Influence of polymer molecular weight and peptide sequence on antimicrobial activity, proteolysis, and biocompatibility | |
| Hou et al. | A concise approach to site-specific topological protein–poly (amino acid) conjugates enabled by in situ-generated functionalities | |
| Oupický et al. | Laterally stabilized complexes of DNA with linear reducible polycations: strategy for triggered intracellular activation of DNA delivery vectors | |
| Nori et al. | Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells | |
| Kopeček et al. | Water soluble polymers in tumor targeted delivery | |
| Henry et al. | pH-responsive poly (styrene-alt-maleic anhydride) alkylamide copolymers for intracellular drug delivery | |
| Unsworth et al. | Protein-resistant poly (ethylene oxide)-grafted surfaces: chain density-dependent multiple mechanisms of action | |
| HRP20141083T1 (hr) | Konjugati faktora viii i polimera | |
| Keefe et al. | Poly (zwitterionic) protein conjugates offer increased stability without sacrificing binding affinity or bioactivity | |
| Shin et al. | Mussel-inspired copolyether loop with superior antifouling behavior | |
| Yu et al. | Proteins conjugated with sulfoxide-containing polymers show reduced macrophage cellular uptake and improved pharmacokinetics | |
| Ahmed et al. | Hyperbranched glycopolymers for blood biocompatibility | |
| JP2018118953A5 (hr) | ||
| KR101512702B1 (ko) | 금속 나노 입자 기반 간 표적 지향 약물 전달체 및 이의 제조방법 | |
| Chen et al. | Polyion complex micelles for protein delivery | |
| WO2008047241A3 (en) | Modified corticotropin releasing factor peptides and uses thereof | |
| WO2011017055A3 (en) | Blood coagulation protein conjugates | |
| WO2008069824A3 (en) | Compositions and methods for transport of molecules with enhanced release properties across biological barriers | |
| ATE374650T1 (de) | Verbesserungen bei polymerteilchen | |
| Bruns et al. | Near-quantitative aqueous synthesis of rotaxanes via bioconjugation to oligopeptides and proteins | |
| Rivas et al. | Functional water‐soluble polymers: polymer–metal ion removal and biocide properties | |
| MX2009005345A (es) | Polimeros anfifilicos de autoensamblaje como agentes antivirales. | |
| EP3093029A8 (en) | Blood coagulation protein conjugates |